A remitted patient with ARFID faces panic after a crash, showing why recovery includes somatic fear, not just eating behavior.
News|Videos|January 16, 2023
New Biomarker Study of Rapid-Acting Treatment for Acute Depression
Author(s)Anantha Shekhar, MD, PhD
Apimostinel is in development for the treatment of acute depressive disorders and depression with suicidality.
Advertisement
Anantha Shekhar, MD, PhD, discusses Gate Neuroscience's phase 1 study of rapid-acting antidepressant, apimostinel.
You can read more about apimostinel in "
Dr Shekhar is senior vice chancellor for the health sciences and John and Gertrude Petersen Dean of the School of Medicine at the University of Pittsburgh. He is also a professor of psychiatry and a professor of clinical and translational science, as well as Chief Scientific Officer of Gate Neuroscience.
Advertisement
Related to this article
Lisa Harding, MD, urges psychiatrists to gather histories, deprescribe safely, and send focused sleep referrals now that orexin agonists have arrived for narcolepsy.
Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Explore PTSD prevalence, comorbidities, and first-line care as we invite clinicians to share cases and research.
Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.
How genes and early stress interact to shape antisocial behavior, from dopamine and serotonin pathways to MAOA and oxytocin findings.
Policy shifts have opened the door to telehealth buprenorphine for pregnant and postpartum women with OUD, but research, guidelines, and state policy lag behind.
Advertisement
Advertisement